Temporal Dynamics of SMARCA4 Loss Define Its Role in Myogenic Differentiation of Alveolar Rhabdomyosarcoma
Abstract
SMARCA4 (BRG1) is a critical ATPase subunit of canonical BAF complexes and a known long-term dependency in alveolar rhabdomyosarcoma (ARMS). To define the short-term consequences of SMARCA4 loss, we used a doxycycline-inducible shRNA system in Rh4 cells. Doxycycline treatment produced strong SMARCA4 knockdown, yet acute knockdown did not alter proliferation or induce myogenic differentiation. Ki-67 positivity remained unchanged, and Myosin Heavy Chain (MHC) expression was absent, indicating preservation of the undifferentiated, proliferative ARMS phenotype. These findings contrast with CRISPR-mediated SMARCA4 knockout studies, which report cell-cycle exit and robust differentiation, suggesting that ARMS cells tolerate partial or early-phase SMARCA4 loss without destabilizing BAF complex function or PAX3-FOXO1–driven regulatory circuitry. Together with prior long-term knockdown studies, our results support a model in which SMARCA4 dependency in ARMS is a sustained phenomenon requiring deep, prolonged suppression to trigger differentiation and loss of tumor viability.